SCHEMBL1646844

SCHEMBL1646844

CC(C)(C)CN1CCN(c2ccc(N)nc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.44
MTOR P42345 5/20 0.44
GCK P35557 2/20 0.43
GCKR Q14397 1/20 0.43
MAPT P10636 2/20 0.41
GAA P10253 2/20 0.41
RAD52 P43351 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GFER P55789 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TRPC6 Q9Y210 3/20 0.38
GLA P06280 1/20 0.37
ATM Q13315 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
DHFR P00374 1/20 0.36
CTSK P43235 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
SUV39H2 Q9H5I1 1/20 0.36
RPS6KA3 P51812 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1992011 0.85 GCK (0.44) PIK3CAMTORGCKGCKRMAPT
SCHEMBL20740560 0.84 HTR2C (0.46) PIK3CAMTORGCKGCKRTRPC6
SCHEMBL30664067 0.83 GAA (0.62) GCKGCKRMAPTGAARAD52
SCHEMBL611882 0.83 GAA (0.62) GCKGCKRMAPTGAARAD52
SCHEMBL17108487 0.80 DRD2 (0.54) PIK3CAMTORMAPTGAARAD52
SCHEMBL30477815 0.80 GCK (0.45) PIK3CAMTORGCKGCKRMAPT
SCHEMBL17108483 0.80 GCK (0.45) PIK3CAMTORGCKGCKRMAPT
SCHEMBL943610 0.79 MAPT (0.66) MTORMAPTGAARAD52KDM4E
SCHEMBL29437380 0.79 PIK3CA (0.42) PIK3CAMTORGCKGCKRMAPT
SCHEMBL2723372 0.79 PIK3CA (0.42) PIK3CAMTORGCKGCKRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 PIK3CA 1546/4885MTOR 439/4885GCK 1080/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 PIK3CA 2774/4885MTOR 2256/4885GCK 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.